Cognoptix,
an emerging medical device company, announced today that its SAPPHIRE
II eye test identified Alzheimer’s disease patients via a beta
amyloid ... read more
Cognoptix
announced today that it has begun a 40-patient clinical trial of its SAPPHIRE
II eye test designed to identify Alzheimer’s disease patients via a beta
... read more
Cognoptix,
an emerging medical device company announced today that its SAPPHIRE
II eye test identified Alzheimer’s disease patients via a beta
amyloid ... read more
Cognoptix, an emerging medical device company previously known as
Neuroptix, announced today that it has exclusively licensed
groundbreaking technology from the University of California at San Diego
... read more